United States· US:0069-1500_f5e01d3a-43fc-4fa6-b5dd-a07330b49328
Xalkori
A crizotinib product containing crizotinib, registered in United States by Pfizer Laboratories Div Pfizer Inc. The same ATC class is registered in 13 of our 19 countries.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
Where it is registered
Crizotinib is registered in 13 of 19 countries.
Countries holding a registration under ATC L01ED01 (crizotinib), each read from that country’s own register.
- This record: United States, from FDA National Drug Code directory (United States)
- 8 of them publish a price we can compare per daily dose
Crizotinib · ATC L01ED01
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
Price per daily dose
What a daily dose of crizotinib costs, country by country.
Normalised to the WHO defined daily dose (0.5 g), so markets compare like for like.
- 1 market with a comparable price for this class
- Public list prices, converted to USD at the rate date shown
Crizotinib · price per daily dose (0.5 g)
USD · FX 28 Sept 2026
- CH Switzerland$203.81
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- CRIZOTINIB
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Country
- United States (US)
- ATC code
- L01ED01
- ATC class
- Crizotinib
- Defined daily dose
- 0.5 g, O
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 2
- ndc11006915006060 CAPSULE, COATED PELLETS in 1 BOTTLE (0069-1500-60)
- ndc110069-1500-60
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
681 interactions on record for crizotinib.
Graded by severity as the source publishes them — 326 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Crizotinib · interactions on record
681 records
- 326 severe
- 338 moderate
- 17 minor
Most severe, free to view
- PapaverineA03AD01severe
- CisaprideA03FA02severe
- OndansetronA04AA01severe
- GranisetronA04AA02severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Crizotinib in 14 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaXALKORIPfizer Europe MA EEIG, Bruxelles
- FinlandXALKORIPfizer Europe MA EEIG
- SpainXALKORI 150 MG GRANULADO EN CAPSULAS PARA ABRIRPfizer Europe Ma Eeig
- BelgiumXalkori 150 mgPfizer Europe MA
- SwitzerlandXalkori 150 mg, filmüberzogenes Granulat zum EinnehmenPfizer AG
- United KingdomXalkori 200mg capsulesOriginalis B.V.
- IcelandXALKORIPfizer Europe MA EEIG*
- NetherlandsXalkori 150 mg, granulaat in capsules om te openenPfizer Europe MA EEIG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Xalkori
- Liechtenstein · Xalkori
- Norway · Xalkori
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/4cf9302d-a783-4e8e-94e1-d4b47f489853 GET /v1/drugs/4cf9302d-a783-4e8e-94e1-d4b47f489853?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "ORAL",
"source": "ndc",
"strength": "150",
"substance": "CRIZOTINIB",
"productndc": "0069-1500",
"dosage_form": "CAPSULE, COATED PELLETS",
"dea_schedule": null,
"strength_unit": "mg/1",
"application_number": "NDA217581",
"marketing_category": "NDA"
}See everything about crizotinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.